Ake­bia scrapes to­geth­er $85M war chest to com­mer­cial­ize va­da as PDU­FA date looms

With its PDU­FA date loom­ing at the end of March, Ake­bia has re­vised its com­mer­cial­iza­tion deal with Vi­for, in­ject­ing a quick $85 mil­lion in­to the biotech to help launch the ane­mia drug vadadu­s­tat in style.

Ac­cord­ing to Ake­bia, it re­vised its pact with Vi­for to add in­de­pen­dent dial­y­sis fa­cil­i­ties to the ros­ter of lo­ca­tions where the drug can be sold. Vi­for al­ready had a deal cov­er­ing the af­fil­i­at­ed Fre­se­nius Kid­ney Care Group in the US. Ake­bia and its part­ners at Ot­su­ka will han­dle the rest of the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER